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Broadly HIV-1–neutralizing antibodies (BnAbs) display one or more unusual traits, including a long heavy 
chain complementarity-determining region 3 (HCDR3), polyreactivity, and high levels of somatic mutations. 
These shared characteristics suggest that BnAb development might be limited by immune tolerance controls. 
It has been postulated that HIV-1–infected individuals with autoimmune disease and defective immune toler-
ance mechanisms may produce BnAbs more readily than those without autoimmune diseases. In this study, 
we identified an HIV-1–infected individual with SLE who exhibited controlled viral load (<5,000 copies/ml) in 
the absence of controlling HLA phenotypes and developed plasma HIV-1 neutralization breadth. We collected 
memory B cells from this individual and isolated a BnAb, CH98, that targets the CD4 binding site (CD4bs) 
of HIV-1 envelope glycoprotein 120 (gp120). CH98 bound to human antigens including dsDNA, which is spe-
cifically associated with SLE. Anti-dsDNA reactivity was also present in the patient’s plasma. CH98 had a 
mutation frequency of 25% and 15% nt somatic mutations in the heavy and light chain variable domains, 
respectively, a long HCDR3, and a deletion in the light chain CDR1. The occurrence of anti-dsDNA reactivity 
by a HIV-1 CD4bs BnAb in an individual with SLE raises the possibility that some BnAbs and SLE-associated 
autoantibodies arise from similar pools of B cells.
Introduction
Broadly HIV-1–neutralizing antibodies (BnAbs) have been 
isolated that bind to multiple epitopes on the envelope glyco-
proteins gp120 and gp41 (reviewed in ref. 1). 2G12 recognizes 
a posttranslational glycan epitope on gp120 (2, 3). CH103–
CH106 (4), b12 (5, 6), VRC01 (7), and numerous other mAbs 
with VRC01-like characteristics, such as VRC03, VRC-PG04, 
CH30–CH34, and the HAAD motif antibodies (7–9), recognize 
the CD4 binding site (CD4bs). HJ16 binds to an epitope near the 
CD4bs (10). PG9 and PG16, CH01–CH04, and PGT141–PGT145 
recognize conformational epitopes in the gp120 V1/V2 region 
with binding dependence on V2 asparagine residue 160 (11–13). 
PGT121–PGT123, PGT135–PGT137, PGT125–PGT128, 
PGT130, and PGT131 recognize a diverse set of carbohydrate or 
carbohydrate-dependent epitopes in the gp120 V3 region (13). 
3BC176 and 3BC315 recognize a conformational HIV-1 spike 
epitope in the proximity of the V3 loop and the CD4i site that 
is exposed in part by CD4 binding (14). Finally, 2F5 (2, 15, 16), 
4E10 (2, 17), 10E8 (18), and Z13 (19) bind to the membrane 
proximal external region (MPER) of gp41.
Each of these antibodies displays one or more unusual charac-
teristics, such as polyreactivity with human and/or nonhuman 
antigens, long heavy chain complementarity-determining region 3 
(HCDR3) loops, and high levels of somatic mutations (1, 13, 20–23). 
These traits suggest that the development of these types of BnAbs 
may be limited by immune tolerance controls that impede the 
required tortuous or polyreactive BnAb maturation pathways (20, 
21, 24). This notion is supported by a number of observations in 
2F5 VH×VL knockin mice: targeted expression of the 2F5 VHDJH/
VLJL rearrangements triggered a near-complete B cell develop-
mental blockade at the pre-B to immature B cell stage (25); even 
when clonal deletion mechanisms were circumvented, 2F5 VHDJH/
VLJL-expressing broadly neutralizing B cell rescue was limited by κ 
chain editing and an anergic phenotype (26); and MPER-specific 
serum neutralizing IgG responses were elicited in 2F5 knockin 
mice immunized with MPER-lipid complexes by rescuing the 
anergic self-reactive 2F5-expressing B cells that survived the B cell 
developmental blockade (26).
We have previously suggested that the paucity of subjects devel-
oping BnAbs may be due to the frequent deletion of B cell precur-
sors that acquire autoreactivity during their maturation process 
(at either early or late stages) and hypothesized that HIV-1–infect-
ed subjects with autoimmune diseases might be capable of devel-
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oping BnAbs in the context of their autoreactive humoral response 
(24, 26–28). The observations that HIV-1 infection is reported with 
a disproportionately low frequency among subjects with SLE sup-
port this hypothesis (29–34).
To date, there have been no reports of studies of the HIV-1 anti-
body repertoire of SLE subjects from whom BnAbs have been 
isolated. Here, we describe CH98, an HIV-1 CD4bs BnAb isolated 
from an HIV-1–infected individual with SLE (subject CH5329; see 
Methods). CH98 displayed a number of unusual antibody traits 
shared by autoimmune disease autoantibodies.
Results
CH5329 plasma neutralization and isolation of CH98. In a multiclade, 
multitier panel of HIV-1 strains, consisting of 4 tier-1A, 4 tier-1B, 
and 34 tier-2 isolates, including 9 transmitted/founder viruses, 
plasma from subject CH5329 neutralized 41 of 42 HIV-1 strains 
(97.6%), with a mean ID50 titer of 925 (range, 21–9,204; Figure 1A). 
The only HIV-1 strain that was not neutralized, G.P0402, was a clade 
G. CH5329 plasma was screened in 2 different but complementary 
assays for CD4bs activity. CH5329 plasma bound to the HIV-1 Env 
resurfaced core 3 (RSC3) protein with a mean endpoint titer 5-fold 
higher than that of the RSC3Δ371I/P363N protein (Figure 1B and 
Supplemental Figure 1; supplemental material available online with 
this article; doi:10.1172/JCI73441DS1), indicative of the presence 
of CD4bs mAbs (7). The RSC3 protein preferentially blocked the 
neutralization ability of CD4bs mAbs such as VRC01, but not mAbs 
directed against other sites, such as the gp41-binding 2F5 BnAb. 
However, the ability of RSC3 protein to block neutralizing activity 
in HIV-infected sera is rare (35) and indicative of the presence of 
CD4bs neutralizing antibodies (7, 8). Therefore, the 30%–55% reduc-
tion we observed in total serum neutralization against 2 different 
HIV-1 strains, HxB2 and JRFL (Figure 1C), indicated that CD4bs 
antibodies markedly contribute to plasma neutralization.
mAb CH98 VHDJH and VLJL gene segments were isolated from a 
clonal memory B cell culture containing 29 ng/ml IgG at the end 
of stimulation with culture supernatant that bound to RSC3 but 
not RSC3Δ371I, and were expressed as a full recombinant IgG1 
mAb (11, 36, 37). CH98 neutralized 27 of 43 HIV-1 isolates (62.8%), 
with a median IC50 neutralization level of 4.2 μg/ml (range, 
<0.02–49 μg/ml), accounting for 65.9% of the observed plasma 
neutralization breadth (Figure 1A). No other antibodies were 
retrieved that bound to RSC3 or neutralized the A.Q23.17 HIV-1 
Figure 1
Identification of neutralizing CD4bs antibodies in CH5329 serum. (A) CH5329 plasma and mAb CH98 neutralization profiles, measured as ID50 and 
IC50,respectively, in TZM-bl assay. Transmitted/founder HIV-1 isolates are italicized. For plasma neutralization: red, ID50 >1,000; orange, ID50 100 to 
1,000; yellow, ID50 >20 and <100; white, ID50 <20 (absence of neutralization). For CH98 BnAb: red, IC50 <1 μg/ml; orange, IC50 1 to 50 μg/ml; white, 
IC50 >50 μg/ml (absence of neutralization). (B) Differential binding by CH5329 serum to the RSC3 protein and the CD4bs knockout RSC3Δ371I/
P363N, graphed as ELISA endpoint titer (final reciprocal serum dilution with background-corrected OD ≥0.1). (C) CD4bs-directed neutralizing 
activity in CH5329 serum, shown as percent reduction in ID80 in the presence of RSC3 compared with the knockout RSC3Δ371I/P363N against 
HIV-1 JRFL and HxB2 strains. Values for the BnAbs VRC01 and 2F5 are included as positive and negative control, respectively. In B and C, error 
bars represent SEM from 2 independent experiments.
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strain, which was selected to screen culture supernatants for het-
erologous neutralizing activity (see Methods). Thus, the frequency 
of peripheral blood circulating CD4bs neutralizing antibodies in 
this subject was estimated to be 0.003%.
Characteristics of CH98. CH98 uses the VH3–30 gene segment, nota-
bly not the VH1–2 or VH1–46 segments commonly associated with 
VRC01-like CD4bs BnAbs (8, 9), paired with the Vλ2–23 light chain 
gene segment. CH98 is highly mutated, with VHDJH and VLJL muta-
tion frequencies of 25.3% and 15.8%, respectively, and displays a long 
HCDR3 of 21 aa (Supplemental Table 1). From 454 pyrosequenc-
ing, we identified 4 additional VHDJH rearrangements in the CH98 
clonal lineage, and all were highly mutated and shared numerous 
mutations with the CH98 VHDJH (Supplemental Figures 2 and 3).
The CH98 light chain CDR 1 (LCDR1) is 27 nt long and under-
went a 15-nt deletion preceded by an activation-induced cytidine 
deaminase (AID) hotspot (AGT; Supplemental Figure 4). TGT motifs 
are also present near the start and the end of this deletion (Supple-
mental Figure 4), raising the hypothesis that slipped-strand synthesis 
may have occurred at this position. It is also worth noting that the 
CH98 VL/JL gene segment rearrangement had a very long n-region 
insertion of 24 nt in the LCDR3 that were not encoded by either of 
the VL2–23 or JL3 germline sequences (Supplemental Figure 4).
CH98 epitope mapping. CH98 bound to RSC3 protein (IC50, 
0.51 μg/ml), but not to RSC3Δ371I/P363N; in contrast to the 
CD4bs BnAb VRC01, CH98 did not bind to RSC3 G367R mutant 
or to the gp120 outer domain stabilized protein OD4.0 (Supple-
mental Table 2). Binding to WT YU2 gp120 Env (IC50, 0.03 μg/ml) 
was abrogated by the D368R mutation, which disrupts a key con-
tact residue within the CD4bs, but not by the I420R mutation 
(IC50, 0.11 μg/ml), which disrupts the CCR5 coreceptor binding 
site (Supplemental Table 2). Also, CH98 potently neutralized the 
HIV-1 YU2 strain (IC50, 0.9 μg/ml). Therefore, we epitope mapped 
CH98 on a panel of YU2 gp120 core protein mutants previously 
used to map other mAbs binding within and outside the CD4bs 
(38, 39). We compared the binding profile of CD4bs BnAb CH98 
with those of other CD4bs BnAbs — CH103 (4), VRC01 (7), CH31–
CH34 (8), and b12 (5, 6) — as well as non-neutralizing CD4bs b6 
mAb and CD4-Fc to 31 YU2 gp120 core single-point mutants (Fig-
ure 2). Single-point mutations outside the CD4bs did not affect 
CH98 binding. Within the CD4bs, mutations in position 365 and 
368 abrogated binding of all CD4bs BnAbs tested, but not mAb 
b6, and mutations in positions 282, 461, and 473 reduced CH98 
binding to 55%, 64%, and 31%, respectively (Figure 2). Overall, 
CH98 was the BnAb least sensitive to the mutations represented 
in the panel, which indicates that these positions are less relevant 
for CH98 binding to its cognate epitope than for the other CD4bs 
BnAbs. The only antibodies sensitive to all the mutations that also 
affected CH98 binding were the BnAbs CH103 and VRC01.
Comparison of CH98 with CD4bs mAbs CH103 and VRC01. CH103 
and VRC01 bind to the CD4bs with 2 distinct modes of epitope 
recognition: CH103 uses a loop dominated mode of interaction 
including all VHDJH and VLJL CDRs (4), whereas VRC01 contacts 
the CD4bs by mimicking CD4 with a large footprint that is domi-
nated by HCDR2 and encompasses both heavy and light chains 
(40). To determine whether CH98 falls into one of these catego-
ries, we threaded the CH98 heavy and light chains onto the gp120-
complexed structure coordinates of CH103 (4) and VRC01 (40).
CH98 threading on the VRC01 gp120-complexed structure 
resulted in steric clashes between the LCDR3 of CH98 and the D 
loop of gp120 (Figure 3A). Relaxation of the model to alleviate the 
Figure 2
Effect of point mutation of the YU2 core protein on CD4-Fc and on 
CH98, CH31–CH34, VRC01 and b12 CD4bs BnAbs, and the non-neu-
tralizing CD4bs b6 mAb. The effect of point mutations on the binding to 
the YU2 core protein of CH98 and other CD4bs mAbs and CD4-Fc is 
expressed as percentage normalized to binding to the WT YU2 gp120 
core protein and color coded as indicated. Positioning within the CD4bs 
(green), or adjacent or nearby (black), is indicated at far right.
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clashes resulted in a complex with a binding energy score of –31.96 
Rosetta energy units (REU; see Methods), which was higher (i.e., 
less favorable) than those of both the solved VRC01-gp120 complex 
and the CH98 complex modeled in the CH103 mode of recognition 
(–40.84, and –37.86 REU, respectively). Conversely, CH98 threading 
onto the gp120-complexed CH103 crystal structure resulted in a 
model compatible with a CH103-like mode of antigen recognition 
(Figure 3B). Between the 2 mAbs, aa sequence homology was 36% 
and 56% for the VHDJH and VLJL, respectively (Supplemental Figure 5 
and Supplemental Table 3). This model supported the observed 
binding data (Figure 2) and predicted that all the heavy and light 
chain CDRs of CH98 make direct contact with the 5 residues affect-
ing CH98 binding to the YU2 gp120 core (Supplemental Table 4).
In particular, D461 was predicted to contact LCDR1 (Supple-
mental Figure 6A), which is 9 aa long and underwent a 5-aa dele-
tion. Therefore, we asked whether a LCDR1 deletion-reverted 
CH98 would be compatible with the gp120-complexed CH103 
mode of recognition. Adoption of the canonical conformation for 
a LCDR1 of length 14, as defined by North and colleagues (41), 
allowed the deletion-reverted LCDR1 to avoid steric clashes at the 
gp120 interface; however, the binding energy score of the complex 
was less favorable than that of the mature CH98 complex (–35.09 
versus –37.86 REU; Supplemental Figure 6B). Our interpretation 
is that the 15-nt deletion in the CH98 LCDR1 may have played a 
favorable role during the process of affinity maturation of CH98.
CH98 BnAb reactivity with human proteins. In a panel of 9 autoanti-
gens associated with presence of autoimmune diseases (Sjogren’s 
syndrome antigens A and B [SSA and SSB, respectively], Smith 
antigen [Sm], ribonucleoprotein [RNP], centromere B [Cent B], 
histone, scleroderma 70 [Scl 70] and Jo-1 proteins, and dsDNA), 
CH98 reacted with dsDNA (Figure 4A). CH98 binding to dsDNA 
was comparable to that previous-
ly observed for the CD4bs BnAb 
CH103 (Supplemental Figure 7). 
In the same assay, CH5329 plas-
ma from the same specimen 
from which CH98 BnAb was iso-
lated was found to be positive for 
SSA and dsDNA antibodies 
(mean ± SD, 268 ± 29 and 163 ± 22 
response units [RU], respectively; 
Figure 4B).
In HEp-2 cell IFA staining, 
CH98 displayed diffuse fine 
granular cytoplasmic stain-
ing, exhibited stronger binding 
to dividing cells, and bound to 
intracellular vesicles in a subset of 
HEp-2 cells (Figure 4, C–E). CH98 
reactivity with 9,400 additional 
human proteins was screened 
using microarray technology (28). 
CH98 showed polyreactivity with 
numerous human antigens, as 
measured by 1 log stronger bind-
ing to more than 90% of the test 
proteins than the non-polyreac-
tive control antibodies 151K and 
palivizumab. CH98 also bound 
with higher affinity, measured 
as a >2 log increase in binding compared with antibody controls, 
to STUB1 (also known as CHIP), an E3 ubiquitin-protein ligase 
(Figure 4, F and G). Binding of CH98 and CH5329 plasma to 
STUB1 were confirmed in direct-binding ELISA with an endpoint 
titer of 3.3 μg/ml for CH98 and plasma titer of 270 (Supplemental 
Figure 8, A and B). We previously demonstrated that members of 
the CD4bs BnAb CH103 clonal lineage displayed reactivity with 
dsDNA and with UBE3A, another E3 ubiquitin-protein ligase (4). 
Such reactivity was also shared by the CD4bs BnAb VRC01 (4). 
However, these BnAbs did not bind to STUB1, and CH98 did not 
bind to UBE3A (data not shown).
Taken together, these findings suggested that the immune 
system dysregulation that allows for production of autoreactive 
antibodies during SLE may have played a permissive role in the 
development and maturation of the BnAb CH98. Moreover, the 
similarities between CH98 and the SLE autoantibodies of long 
HCDR3 and dsDNA reactivity are suggestive of similar pools of B 
cells and mechanisms of their origin.
Discussion
Here, we describe an individual who, when studied 14 years after 
HIV-1 transmission and 6 years after onset of SLE, controlled 
her viral load off antiretroviral therapy (ART) and developed 
plasma BnAb activity.
An open question regarding the development of BnAbs in HIV-1–
positive subjects is whether acquisition of autoreactivity is a com-
mon prerequisite for the development of neutralization breadth. 
We have previously described the CH103 CD4bs BnAb isolated 
from an SLE-negative, chronically HIV-1–infected individual and 
demonstrated that antibodies in the CH103 clonal lineage acquired 
autoreactivity with a number of autoantigens, including dsDNA, 
Figure 3
Threading of CH98 onto the gp120 complexed structures of CD4bs VRC01 and CH103 BnAbs. (A) CH98 
model based on threading onto the gp120 complexed VRC01 crystal structure. The CH98 heavy chain (HC; 
dark blue) and light chain (LC; light blue) threaded onto the VRC01 structure complexed with gp120 (gray) 
resulted in an incompatible model, with a clash between the gp120 D loop (red) and the LCDR3 (green). 
(B) CH98 model based on threading onto the gp120 complexed CH103 crystal structure. The CH98 heavy 
chain (dark blue) and light chain (light blue) threaded onto the CH103 structure complexed with gp120 (gray) 
resulted in a model in which HCDR3 (magenta) dominates the binding to the CD4bs region and engages 
in direct contact with gp120 residues in positions 365, 368, 473, and 282, all of which affect CH98 binding. 
The residue in position 461 makes direct contact with LCDR1. Each residue that affects CH98 binding in the 
epitope mapping is illustrated using the corresponding color in Figure 2.
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concurrently with acquisition of HIV-1 neutralization breadth (4). 
We have also described an individual in whom the onset of gp41 
MPER 2F5-like BnAb plasma activity was temporally associated 
with the development of plasma dsDNA and Jo-1 autoantigen reac-
tivity, without appearance of any clinical manifestation of autoim-
mune disease (42). Thus, in some individuals, acquisition of BnAb 
activity is clearly associated with the acquisition of autoreactivity.
Antibodies to dsDNA are a hallmark of SLE and are present in 
approximately 70% of subjects with SLE, but only 0.5% of SLE-
negative individuals (32). Conversely, dsDNA antibodies are not a 
typical finding during HIV-1 infection, but have been commonly 
reported in the plasma of the few SLE subjects with HIV-1 infec-
tion (30, 33). The presence of plasma dsDNA antibodies has been 
documented in subjects diagnosed with SLE both after and before 
HIV-1 diagnosis (91.7% and 64.3%, respectively) (30). The incidence 
of plasma BnAbs in these reported cases, however, is unknown.
We report herein a monoclonal HIV-1 BnAb, CH98, isolated 
from a chronically HIV-1–infected individual who subsequently 
developed SLE. CH98 neutralized HIV-1 through binding to the 
CD4bs on HIV-1 gp120 and reacted with dsDNA at levels compa-
rable to those previously observed for the CD4bs BnAb CH103. 
CH98 accounted for only a portion of the plasma neutralization 
breadth (65.9%). This observation, in conjunction with the find-
ing that RSC3 plasma absorption only partially abrogated plas-
ma neutralization (30%–55%), implies that other neutralizing 
antibody specificities contributed to the overall plasma neutral-
ization breadth in this individual. These data are in line with pre-
vious observations indicating that plasma neutralization breadth 
can be mediated by a polyclonal response comprising antibodies 
with distinct specificities and variable degrees of breadth (43–45). 
Using a combination of epitope mapping and threading of the 
CH98 heavy and light chains onto the gp120-complexed struc-
ture coordinates of CD4bs BnAbs, we determined that CH98 
likely uses a CH103-like Env loop mode of epitope recognition 
that involves all the heavy and light chain CDRs. Conversely, 
CH98 threading onto the gp120-complexed structure of VRC01 
resulted in steric clashes between the LCDR3 of CH98 and the 
D loop of gp120. This result was not unexpected: VRC01 and 
all VRC01-like antibodies had unusually short LCDR3s (5 resi-
dues), and it has been suggested that the VRC01-like orienta-
tion of gp120 binding does not leave enough space between the 
antibody and the gp120 D loop to accommodate longer LCDR3s 
(46). Indeed, CH98 has a 12-residue-long LCDR3, and therefore 
our model is compatible with this hypothesis.
Figure 4
Autoreactivity of CH98. (A) CH98 
reactivity against common anti-
gens associated with autoimmune 
diseases, tested with a commer-
cial ANA-II Plus test system. The 
threshold for positivity was 120 RU 
(dashed line). (B) CH5329 plasma 
reactivity against common anti-
gens associated with autoimmune 
diseases, tested with the com-
mercial ANA-II Plus test system. 
Results from 3 independent exper-
iments are shown. The thresh-
old for negativity was 100 RU 
(solid line), and that for positiv-
ity was 120 RU (dashed line); 
values of 100–120 RU were 
considered equivocal speci-
mens. (C–E) Hep-C IFA stain-
ing of BnAb CH98. Antibody 
concentration was 25 μg/ml, 
and exposure time was 8 seconds. 
Original magnification, ×40; inset 
in D is enlarged ×1.5. (F and G) 
Reactivity of CH98 on a panel of 
9,400 human proteins tested using 
a ProtoArray 5 microchip, com-
pared with nonautoreactive mAb 
151K (F) or palivizumab (G). Val-
ues for STUB1 are encircled.
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CH98 was also characterized by a short LCDR1 (9 aa) that 
underwent a 5-aa deletion during the process of affinity matura-
tion. This 15-nt deletion in CH98 LCDR1 was preceded by an AID 
hotspot. AID hotspots regulate secondary antibody diversifica-
tion and are directly involved in the process of somatic hypermu-
tation (47, 48). Since we predicted a less favorable binding energy 
score of the deletion-reverted CH98 complex compared with the 
mature CH98 complex, our interpretation is that, similar to our 
prior observation for CH103 (4), a single macromutation may have 
improved binding to the cognate epitope. In addition, LCDR1s 
shorter than 11 aa are rare (46), but commonly found among 
CD4bs BnAbs (4, 46), and both CH103 and VRC01 also have dele-
tions in their LCDR1s (4, 40). We interpret the disproportionate 
frequency of short LCDR1s among CD4bs BnAbs as being indica-
tive of a common selection process of CD4bs BnAbs that favors 
antibodies with shortened LCDR1s.
This is the first chronically infected SLE individual with con-
comitant HIV-1 infection that we have been able to study, and it 
was striking that this individual also had robust plasma BnAb 
activity, given that the incidence of chronically HIV-1–infected 
subjects with this level of plasma neutralization breadth is only 
approximately 20% (49–52).
In a literature review from 1981 to 2012 by Carugati and col-
leagues, of 53 HIV-1/SLE patients, 54.7% were diagnosed with 
HIV-1 before SLE (33). The diagnosis of HIV-1 in our subject 
preceded that of SLE, and we cannot conclude that the CH98 
maturation was initiated as part of the SLE-induced autoreactive 
response, nor can we exclude the possibility that silent SLE was 
present before the time of HIV-1 diagnosis.
When generated, BnAbs appear late (2–4 years) after HIV-1 trans-
mission, and serum neutralization breadth correlates with viral 
load levels (49). This has been interpreted as an indication that per-
sistent antigen stimulation is required to develop neutralization 
breadth (53–55). In stark contrast, our study subject developed 
BnAbs while controlling viremia, which suggests that acquisition 
of HIV-1 neutralization breadth may not always require chronic 
stimulation with high levels of HIV-1 viremia. A possible explana-
tion is that the maturation of CH98 was not hindered in this sub-
ject by immune tolerance control mechanisms, thus facilitating 
the acquisition of mutations required to achieve neutralization 
breadth, possibly driven by exposure to both HIV-1 and autoanti-
gens (21, 24, 27). The low viral load and normal CD4 count of this 
subject while off ART could not be explained by HIV-1–controlling 
HLA types (56) or by HIV-1 infection with a nef-defective strain 
(57, 58); studies are in progress to determine whether the presence 
of SLE contributed to virus control.
Kobie and colleagues recently identified an autoreactive plasma 
antibody population (9G4 anti-idiotype antibodies) that is com-
monly found in SLE subjects and is responsible for serum HIV-1 
neutralization breadth in ART-naive, SLE-negative, chronically 
HIV-1–infected subjects; the authors proposed that this kind of 
antibody may derive from the same pool of B cells of SLE-induced 
antibodies (34). The BnAb CH98 differs from 9G4-positive antibod-
ies in that it uses a VH3–30 gene segment, not VH4–34, which defines 
9G4 antibodies. Therefore, our findings demonstrated that autore-
active antibody populations beyond 9G4-positive antibodies have 
the potential to broadly neutralize HIV-1 strains in SLE subjects.
In conclusion, we demonstrated that a virus-controller SLE 
patient with chronic HIV-1 infection developed the highly mutat-
ed CD4bs BnAb CH98, and this antibody displayed characteris-
tics typical of SLE-induced autoantibodies. Our findings support 
the hypothesis that lax mechanisms of tolerance control associ-
ated with SLE may have favored the maturation of this BnAb by 
favoring its evasion from deletion during the process of somatic 
maturation and the acquisition of reactivity with self-antigens. 
Moreover, our data support the concept that BnAbs develop from 
a similar pool of B cells as do autoimmune B cells in SLE.
Methods
Patient information. Subject CH5329 is a female patient, aged 33 years at the 
initiation of the study. At 19 years of age, the patient was diagnosed with 
HIV-1; at 27 years of age (8 years after HIV-1 diagnosis), the subject was diag-
nosed with SLE. The patient sought health care at the Duke University Medi-
cal Center Clinics in 2009 (age 31 years). At admission, her general health 
conditions were overall good with no fever, chills, night sweats, nausea, vom-
iting, or diarrhea. CD4 count was 460 cells/mm3. She had not received any 
ART. SLE diagnosis was confirmed at admission based on American College 
of Rheumatology criteria for SLE (59): malar rash, discoid rash, photosensi-
tivity, arthritis, and presence of plasma speckled anti-nuclear antibody titer 
of 160. The subject also reported a history of seizures that preceded the diag-
nosis of both SLE and HIV-1 infection, as well as a history of asthma, which 
was controlled by daily triamcinolone and albuterol. In 2009, her plasma was 
negative for SSA, SSB, RNP, Sm, and dsDNA antibody. Serum complement 
levels were normal. Her SLE was treated with plaquenil from 2005 to January 
2008 and 7.5 mg methotrexate once weekly from 2006 to December 2012, 
when plaquenil was restarted and continued up to date.
The patient was enrolled in 2011 in the CHAVI008A study of chronic 
HIV-1–infected individuals. Plasma, PBMCs, and leukapheresis samples 
were collected and studied. At enrollment, the subject had received no 
ART, and her CD4 count and viral load were 568 cells/mm3 and 4,150 HIV 
RNA copies/ml, respectively. Her MHC class I phenotype was HLA-B7 and 
HLA-B40. Analysis of 64 HIV-1 3′-half genome sequences generated by 
the single genome amplification method showed the intact nef gene in all 
sequences (Supplemental Figure 9). In 2011, her plasma was positive for 
dsDNA antibodies; negative for SSA, SSB, Sm, RNP, Scl 70, Jo-1, Cent B, 
and histone antibodies; and showed an ANA-positive pattern in HEp-2 cell 
intracellular fluorescence staining with an endpoint titer of 320.
Cell cultures. IgG+ memory cells were isolated from PBMCs as previously 
described (11). Briefly, IgG+ memory B cells were isolated from frozen 
PBMCs by 2 rounds of separation using magnetic beads (11). First, PBMCs 
were incubated for 30 minutes at 4°C with PE-conjugated anti-CD2 (cata-
log no. 555327), anti-CD14 (catalog no. 555398), anti-CD16 (catalog no. 
555407), anti-CD235a (catalog no. 555570), and anti-IgD (catalog no. 
555779) antibodies (all from BD Biosciences — Pharmingen), followed 
by a 15-minute incubation with anti-PE microbeads (Miltenyi Biotec) at 
4°C. After washing, cells were passed through magnetic columns using 
the Deplete_S program of the AutoMACs separator (Miltenyi Biotec). 
The negative fraction was then incubated for 15 minutes with anti-IgG 
microbeads (catalog no. 130-047-501; Miltenyi Biotec). After washing, IgG+ 
memory B cells were selected using the Possel_S program of the AutoMACs 
separator (11). All steps of the separation procedure were performed using 
cold PBS with 0.1% BSA buffer (PBSB). IgG+ memory B cells were stimu-
lated for 14 days in vitro to induce proliferation and differentiation into 
antibody-secreting cells for functional studies on the culture supernatants, 
using a previously described stimulation protocol (11). Briefly, cells were 
resuspended in complete medium containing 2.5 μg/ml CpG ODN2006 
(tlrl-2006; InvivoGen), 5 μM CHK2 kinase inhibitor (Calbiochem/EMD 
Chemicals), and EBV (200 μl supernatant of B95-8 cells/104 memory B 
cells) and incubated in bulk overnight at 37°C in 5% CO2 (11). After over-
night incubation, 28,800 viable IgG+ memory B cells were manually trans-
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ferred at an average density of 3 cells/well in 96-well round-bottomed tis-
sue culture plates containing ODN2006, CHK2 kinase inhibitor, and 5,000 
irradiated (7,500 cGy) CD40 ligand–expressing L cells per well. The cell 
density of 3 cells per well was chosen to achieve the expansion of a single 
cell in the majority of wells, according to Poisson distribution and previ-
ous experimental observations using this method. Medium was refreshed 
after 7 days, and supernatants were harvested at day 14 (11). Cell culture 
supernatants were screened for IgG levels, differential binding to RSC3 
and RSC3Δ371I, and neutralization of the clade A.Q23.17 HIV-1 strain. 
This screening strategy was selected to isolate BnAbs based on the observed 
plasma differential binding to RSC3 and RSC3Δ371I and the high plasma 
ID50 A.Q23.17 HIV-1 strain neutralization. The RSC3 gp120 core antigen 
is a protein designed to retain the antigenic structure of the neutralizing 
surface of the CD4bs while eliminating other antigenic regions of the 
HIV-1 envelope glycoprotein, and the deletion of a single aa in position 371 
(RSC3Δ371I; originally described as ΔRSC3) abrogates or heavily reduces 
the binding of CD4bs BnAbs (7). Since CD4bs BnAbs such as VRC01, 
VRC01-like, and CH103 have been previously isolated from memory B 
cells that bound to RSC3 using antigen-specific cell sorting (4, 7, 44, 60), 
we decided to use this protein to screen cultured memory B cells cultured 
to retrieve CD4bs BnAbs using our culture system.
Isolation of V(D)J Ig regions and expression of recombinant antibody. RNA from 
positive cultures was extracted using standard procedures (RNeasy mini-
kit; Qiagen), and the genes encoding Ig VHDJH and VLJL rearrangements 
were amplified by RT and nested PCR without cloning, using a previously 
reported method (11, 36). Briefly, reverse transcription was performed at 
55°C for 1 hour after the addition of 50 U/reaction of Superscript III RT 
(Life Technologies) and 0.5 μM human IgG, IgM, IgD, IgA1, IgA2, Igκ, and 
Igλ constant-region primers. Separate reactions were used to amplify indi-
vidual families of VH, Vκ, and Vλ genes from the cDNA template; this was 
performed using 2 rounds of PCR: first round, 5 μl RT reaction product, 
5 U HotStar Taq Plus (Qiagen), 0.2 mM deoxynucleoside triphosphates 
(dNTPs), 0.5 μM nested constant-region primers (IgH consisting of IgM, 
IgD, IgG, IgA1 and IgA2; Igκ or Igλ), and matched variable-region prim-
ers; second round, 2.5 μl first-round reaction product, 5 U HotStar Taq 
Plus, 0.2 mM dNTPs, 0.5 μM nested constant-region and nested variable-
region primers. First-round PCR was cycled as follows: 95°C for 5 minutes; 
35 cycles at 95°C for 30 seconds, 55°C (VH and Vκ) or 50°C (Vλ) for 60 seconds, 
and 72°C for 90 seconds; and 1 cycle at 72°C for 7 minutes. Second-round 
PCR was similar, except that the extension step was performed at 58°C 
(VH), 60°C (Vκ), or 64°C (Vλ). Samples of VH, Vκ, and Vλ chain PCR prod-
ucts were analyzed on 2% agarose gels (Qiagen). Products were sequenced 
in the forward and reverse directions using a BigDye sequencing kit on 
an ABI 3700 instrument (Applied Biosystems). Sequence base calling was 
performed by using Phred. V, D, and J region genes and mutations were 
analyzed using the SoDA information system (61). All primers used for the 
second round of PCR included tag sequences at the 5′ end of each primer 
to permit the assembly of the VH and VL genes into functional linear Ig 
gene expression cassettes by overlapping PCR, as reported elsewhere (36).
Expression of recombinant antibody. Isolated Ig VHDJH/VLJL gene pairs were 
assembled by PCR into linear full-length Ig heavy- and light-chain gene 
expression cassettes as previously described (36). The human embryonic 
kidney cell line 293T (ATCC) was grown to near confluence in 6-well tissue 
culture plates (BD) and transfected with 2 μg/well purified PCR-produced 
IgH and IgL linear Ig gene expression cassettes using Effectene (Qiagen). 
Supernatants were harvested from the transfected 293T cells after 3 days 
of incubation at 37°C in 5% CO2.
Neutralization assays. Neutralizing antibody assays with TZM-bl cells were 
performed as previously described (62). Purified recombinant antibodies 
were tested starting at a 50-μg/ml final concentration and titrated using 
serial 3-fold dilutions. Plasma antibody was tested starting at a 1:20 dilu-
tion. Pseudotyped lentiviruses were added to the antibody dilutions at a 
predetermined titer to produce measurable infection and incubated for 
1 hour. TZM-bl cells were added and incubated for 48 hours before lysis, 
after which the supernatant was measured for firefly luciferase (Britelite 
Plus; Perkin-Elmer) activity using a luminometer. Data were calculated as 
the reduction in luminescence compared with control wells and reported 
as IC50 (in μg/ml) for purified recombinant antibodies or ID50 titer (as 
1/dilution) for plasma (62). Plasma neutralization resistance was defined 
as an ID50 titer <20. For further information on the viruses used for neu-
tralization screening, see Supplemental Table 5.
Direct binding ELISAs. Direct binding assays were performed in 384-well 
plates as previously described (11). Briefly, plates were coated overnight at 
4°C with 15 μl purified proteins at optimized concentrations and blocked 
with assay diluent (PBS containing 4% [w/v] whey protein, 15% normal goat 
serum, 0.5% Tween 20, and 0.05% sodium azide) for 2 hours at room temper-
ature. Primary culture supernatants were screened at a 1:3 dilution in assay 
diluent, whereas purified recombinant antibodies were tested using 3-fold 
serial dilutions starting at 100 μg/ml. 10 μl of primary antibodies were 
added to each well and incubated for 2 hours at room temperature. Plates 
were developed using 15 μl/well horseradish peroxidase–conjugated goat 
anti-human IgG Fc (catalog no. 109-035-098; Jackson ImmunoResearch 
Laboratories) at a 1:9,000 dilution in 5% goat serum and PBS for 1 hour, 
followed by 30 μl/well of SureBlue Reserve TMB One Component microwell 
peroxidase substrate (catalog no. 53-00-03; KPL). Development was 
stopped with 15 μl/well of 0.1 M HCl, and plates were read at OD450 with a 
VersaMax microplate reader (Molecular Devices).
HEp-2 cell staining. Indirect immunofluorescence binding of mAbs or plas-
ma to HEp-2 cells (Zeuss Scientific) was performed as previously described 
(24). Briefly, 20 μl of antibody at 50 μg/ml or plasma in serial dilutions was 
aliquoted onto a predetermined spot on the surface of a slide (ANA HEp-2 
kit). After incubation for 25 minutes at room temperature and washes, 
20 μl of secondary antibody (goat anti-human Ig FITC at 20 μg/ml; South-
ern Biotech) was added to each spot and incubated in a humid chamber for 
25 minutes in the dark. After washing and drying, a drop of 33% glycerol 
was added to each spot, and the slide was covered with a 24- by 60-mm 
coverslip. Images were taken on an Olympus AX70 instrument with a Spot-
Flex FX1520 CCD and with a UPlanFL 40× 0.75-NA objective at 25°C in 
the FITC channel using SPOT software. All images were acquired for 8 or 
10 seconds. Image layout and scaling were performed with Adobe Photo-
shop without image manipulation.
Antibody reactivity against human host cellular antigens. Binding of CH98 to 
human host cellular antigens was performed using a ProtoArray 5 micro-
chip (Life Technologies) according to the manufacturer’s instructions. In 
brief, ProtoArray 5 microchips were blocked and exposed to 2 μg/ml CH98 
or a human myeloma protein (151 K; Southern Biotech), or palivizumab for 
90 minutes at 4°C. Protein-antibody interactions were detected by 1 μg/ml 
Alexa Fluor 647–conjugated anti-human IgG. The arrays were scanned at 
635 nm with 10-μm resolution, using 100% power and 600 gain (GenePix 
4000B scanner; Molecular Devices). Fluorescence intensities were quantified 
using GenePix Pro 5.0 (Molecular Devices). Lot-specific protein spot defini-
tions were provided by the microchip manufacturer and aligned to the image.
Epitope mapping. A panel of 32 HIV-1 YU2 gp120 core mutants displayed 
on S. cerevisiae (38) was probed for binding to CD4bs mAbs and CD4-Fc 
(Sino Biological). For each core mutant, 600,000 induced yeast cells were 
incubated with anti-HA Ab clone 16B12 (Covance) to detect expression 
and CD4bs mAbs or CD4-Fc in 50 μl PBSB in black 96-well plates (Greiner 
Bio One) for 1 hour at room temperature while shaking. Yeast cells were 
washed twice with 200 μl cold PBSB and subsequently incubated with 
goat anti-mouse and anti-human detection antibodies conjugated to 
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Alexa Fluor 488 or Alexa Fluor 647 (Life Technologies) in 50 μl PBSB for 
20 minutes shaking at room temperature and covered from light. Yeast 
cells were washed once as above, suspended in 200 μl PBSB, and analyzed 
for fluorescence using a MACSQuant (Miltenyi Biotec) flow cytometer. For 
each mutant, 10,000 events were gated on HA signal, and median fluo-
rescence intensities (MFIs) were determined and normalized for expres-
sion. This method has been previously used to test approximately 2 dozen 
mAbs (binding within and outside the CD4bs), and the observed results 
were consistent both with crystal structures whenever they were avail-
able and with epitope maps generated by other means, whether or not the 
cocrystals/other maps were generated with YU2 (38, 39). Additionally, fine 
specificity differences in the residues identified as involved in binding for 
multiple antibodies have been found to correlate with either broad or nar-
row neutralization activity (S.K. Grimm and M.E. Ackerman, unpublished 
observations), further supporting the validity of the method.
CH98 homology modeling. Homology models of CH98 in complex with 
gp120 were built using Rosetta protein modeling software (63). The 
sequence of the heavy and light chains of CH98 were threaded indepen-
dently onto the template’s (CH103, ref. 4; VRC01, ref. 40) heavy and light 
chain structures (PDB codes 4JAN and 3NGB, respectively). The best-
scoring heavy and light chain models from the independent threading 
runs were then superposed onto the paired heavy and light chain tem-
plate, and this model was allowed to relax using the Rosetta FastRelax 
protocol. After relaxation, the model was minimized with AMBER (64). 
This homology model of the unliganded antibody was then superposed 
into the solved antibody-gp120 complex structure. The Rosetta loop 
refinement protocol (65) was used to allow for loop flexibility in the V5 
loop of gp120 (a superposition of solved gp120 structures from the PDB 
indicated the V5 loop to be the most flexible loop in the CD4 binding 
site) and the HCDR3 loop (the most flexible of the 6 CDR loops; ref. 66). 
The top-scoring complex model after loop refinement then underwent 
a last round of relaxation with Rosetta to further refine the complex. A 
model of the LCDR1 deletion-reverted CH98 complex was built using 
the above homology modeling procedure using the CH98 mature light 
chain sequence with the 5-aa GSYNL insertion in LCDR1. One additional 
step was added to the procedure that placed the LCDR1 in its canonical 
conformation based on length and sequence using the CDR structural 
definitions of North and colleagues (41). Predicted binding energy scores 
for all modeled complexes were computed in Rosetta by subtracting the 
energy score of the antibody and gp120 alone from the energy score of the 
antibody-gp120 complex and expressed as REU.
Preparation of libraries for 454 DNA pyrosequencing. V, D, and J segments 
of the Ig heavy chain were amplified and sequenced using the 454 pyro-
sequencing platform as previously described (8). Briefly, a cDNA library 
was constructed by isolation of mRNA from 22 × 106 PBMCs using 
the Oligotex kit (Qiagen) and concentrated to 26 μl in elution buffer. 
Reverse transcription was performed in 2 35-μl reactions (13 μl mRNA, 
3 μl oligo(dT)12–18 at 0.5 μg/μl [Invitrogen], 7 μl 5× first-strand buffer 
[Invitrogen], 3 μl RNase Out [Invitrogen], 3 μl 0.1M DTT, 3 μl dNTP mix, 
each at 10 mM, and 3 μl SuperScript II [Invitrogen]) and incubated at 
42°C for 2 hours. The cDNA was combined, purified, and eluted in 20 μl 
elution buffer (NucleoSpin Extract II kit; Clontech). Heavy and light chain 
variable region rearrangements were amplified by PCR from 5 μl cDNA 
as template (the rough equivalent of transcripts from 5.5 × 106 PBMCs) 
using the Phusion High Fidelity enzyme (New England Biolabs) according 
to the manufacturer’s instructions. The 50 μl reaction mix was composed 
of water, 10 μl 5× buffer, 1 μl dNTP mix, each at 10 mM, 1 μl of each prim-
er at 25 μM, and 1 μl enzyme. Gene-specific forward primers for VH3 gene 
amplification were VH3 Leader A, C, D, E, and F, and the reverse primers 
were 3′Cγ-CH1 and 3′Cμ-CH1 (8, 67). The forward primer for VL2 ampli-
fication was 5′L-VL1/2-5′-GCACAGGGTCCTGGGCCCAGTCTG-3′, and 
the reverse primer was 3′CL-5′-CACCAGTGTGGCCTTGTTGGCTTG-3′. 
The PCR cycling program was run according to Phusion enzyme instruc-
tions, using 55°C as the annealing temperature for the heavy chain reac-
tion and 66°C for the lambda. The PCR products at the expected size 
(450–500 bp) were gel purified (Qiagen), followed by phenol/chloroform 
extraction. 454 pyrosequencing of the PCR products was performed on 
a GS FLX sequencing instrument (Roche-454; Life Sciences) using the 
manufacturer’s suggested methods and reagents.
Statistics. Values were expressed as mean ± SEM of 2 independent experi-
ments where indicated. Statistical analysis was performed using GraphPad 
Prism 5 (GraphPad Software). 
Study approval. This study was approved by the Duke IRB and the NIH 
NIAID DAIDS PSRC committee. Informed consent was received from the 
participant prior to inclusion in the study according to U.S. federal, local, 
and Duke University Medical Center regulations.
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